CPA
BMRN icon

Capital Performance Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capital Performance Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,844
Closed -$201K – 278
2025
Q1 		$201K Buy
+2,844
New +$191K 0.04% 244
2024
Q4 		– Sell
-168
Closed -$11.8K – 512
2024
Q3 		$11.8K Buy
+168
New +$14K ﹤0.01% 771

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Performance Advisors's BMRN Position: Q2 2025 in Review

Capital Performance Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 2,844 shares — an estimated $201K sold.

Capital Performance Advisors first reported a position in BMRN in Q3 2024 and held it in 2 quarters. The position peaked at $201K in Q1 2025. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

  • Capital Performance Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Capital Performance Advisors sold 2,844 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $201K.
  • Capital Performance Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Capital Performance Advisors's BioMarin Pharmaceuticals position peaked at $201K in Q1 2025.
  • 581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Capital Performance Advisors's 13F filing for Q2 2025, filed 4 Aug 2025.